Format

Send to

Choose Destination
Breast Cancer Res Treat. 2018 Oct 27. doi: 10.1007/s10549-018-4992-7. [Epub ahead of print]

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.

Author information

1
Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
2
Department of Public Health Sciences, MUSC, Charleston, SC, USA. fordmar@musc.edu.
3
Hollings Cancer Center, MUSC, Charleston, SC, USA. fordmar@musc.edu.
4
James E. Clyburn Research Center Medical University of South Carolina, Charleston, SC, 29425, USA. fordmar@musc.edu.
5
Department of Exercise Science, College of Arts and Sciences, Campbell University, Buies Creek, NC, USA.
6
Hollings Cancer Center, MUSC, Charleston, SC, USA.
7
Department of Public Health Sciences, MUSC, Charleston, SC, USA.
8
Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA.
9
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
10
Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD, USA.
11
Dietetic Services, MUSC, Charleston, SC, USA.
12
Department of Medicine/Renal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
13
Department of Anesthesia and Perioperative Medicine, MUSC, Charleston, SC, USA.
14
Department of Medicine, Division of Cardiology, MUSC, Charleston, SC, USA.
15
Department of Surgery, MUSC, Charleston, SC, USA.
16
Washington University School of Medicine, St. Louis, MO, USA.
17
College of Nursing, MUSC, Charleston, SC, USA.
18
Department of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA. turnerda@musc.edu.
19
Department of Public Health Sciences, MUSC, Charleston, SC, USA. turnerda@musc.edu.
20
James E. Clyburn Research Center Medical University of South Carolina, Charleston, SC, 29425, USA. turnerda@musc.edu.

Abstract

PURPOSE:

Lifestyle factors associated with personal behavior can alter tumor-associated biological pathways and thereby increase cancer risk, growth, and disease recurrence. Advanced glycation end products (AGEs) are reactive metabolites produced endogenously as a by-product of normal metabolism. A Western lifestyle also promotes AGE accumulation in the body which is associated with disease phenotypes through modification of the genome, protein crosslinking/dysfunction, and aberrant cell signaling. Given the links between lifestyle, AGEs, and disease, we examined the association between dietary-AGEs and breast cancer.

METHODS:

We evaluated AGE levels in bio-specimens from estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer patients, examined their role in therapy resistance, and assessed the ability of lifestyle intervention to reduce circulating AGE levels in ER+ breast cancer survivors.

RESULTS:

An association between ER status and AGE levels was observed in tumor and serum samples. AGE treatment of ER+ breast cancer cells altered ERĪ± phosphorylation and promoted resistance to tamoxifen therapy. In a proof of concept study, physical activity and dietary intervention was shown to be viable options for reducing circulating AGE levels in breast cancer survivors.

CONCLUSIONS:

There is a potential prognostic and therapeutic role for lifestyle derived AGEs in breast cancer. Given the potential benefits of lifestyle intervention on incidence and mortality, opportunities exist for the development of community health and nutritional programs aimed at reducing AGE exposure in order to improve breast cancer prevention and treatment outcomes.

KEYWORDS:

Advanced glycation end product; Breast cancer; Estrogen receptor; Lifestyle intervention; Tamoxifen resistance

PMID:
30368741
DOI:
10.1007/s10549-018-4992-7

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center